



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Jim Justice
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Bill J. Crouch
Cabinet Secretary

Pharmaceutical and Therapeutics
Committee
August 26th, 2017

Location: Diamond, Rooms B10 and B11
Time: 2:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Committee Members Present:

Bradley Henry, M.D., Chair
Tom Kines, R.Ph., Vice-Chair
Chris Terpening, Pharm.D., PhD.
Heather Jones
Hazi Nazha, M.D.
Steve Neal, Pharm.D
Toni DiChiacchio, DNP
Karrie Juengel, Pharm.D
Mary Payne, MD

By Phone:

Absent:
Kenneth Hilsbos, M.D.

Division of Medicaid Staff Present:

Vicki Cunningham, R.Ph.
Brian Thompson, Pharm.D., MS
Doug Sorvig

Contract Staff/CHC Staff Present:

Brent Breeding, R.Ph
Laureen Bizcak, MD
Jennifer Seymour, Operational Account
Coordinator (by phone)

Other Contract / State Staff Present:

Steve Small, R.Ph., MS, RDTP

I. Call to Order

Dr. Bradley Henry, Chairman, called the meeting to order at 2:06pm

II. Welcome and Introductions

P&T committee members introduced themselves.

III. Administrative Items / Updates

Vicki Cunningham provided ground rules for public comment.

a) Approval of the April 26th, 2017 Minutes

Tom Kines made a motion to approve the minutes from the April 26th meeting, the motion was seconded by Toni DiChiacchio. All were in favor and the minutes were approved.

b) PDL Compliance/Generic Percent Report Updates

Dr. Biczak walked the committee through the Generic Percent and PDL Compliance reports provided to the Committee. PDL compliance was high overall. In some categories, with less generic use, PDL compliance was high, owing to preferred brands.

IV. Public Comments

Jeremy Soule representing Sanofi spoke on behalf of SOLIQUA.

Jennifer Wilbanks representing Sunovion spoke on behalf of Utibron.

Andrea Wilson representing Boehringer Ingelheim spoke on behalf of Jardiance.

Joseph Loftis representing Novo-Nordisk spoke on behalf of Xultophy.

Mark Veerman representing Janssen spoke on behalf of Invokana.

Kevin Lynch representing Pfizer spoke on behalf of Encrisa.

V. Executive Session

A motion was made to move to executive session. The motion was seconded and all were in favor.

The Committee adjourned for executive session at 2:30pm.

The Committee reconvened at 3:16pm.

VI. New Business

A. Adjustments to Existing Classes

i. BETA BLOCKER/DIURETIC COMBINATION DRUGS

BETA BLOCKERS ^{AP}	
BETA BLOCKER/DIURETIC COMBINATION DRUGS	
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ propranolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol ER/HCTZ ER) LOPRESSOR HCT (metoprolol/HCTZ) metoprolol/HCTZ ^{ER} nadolol/bendroflumethiazide TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)

Chris Terpening made a motion to approve the change to the Beta Blocker/Diuretic Combination Drug class as recommended; the motion was seconded by Steve Neal. All members were in favor and the motion was approved.

ii. HYPOGLYCEMICS, SGLT2 INHIBITORS

HYPOGLYCEMICS, SGLT2 INHIBITORS	
SGLT2 INHIBITORS	
JARDIANCE (empagliflozin)	FARXIGA (dapagliflozin) INVOKANA (canagliflozin)

Steve Neal made a motion to approve the change to the Hypoglycemics, SGLT2 Inhibitors class as recommended; the motion was seconded by Karrie Juengel. All members were in favor and the motion was approved.

B. New Generics

i. Aprepitant

ANTIEMETICS ^{AP}	
SUBSTANCE P ANTAGONISTS	
EMEND (aprepitant)	aprepitant VARUBI (rolapitant)

ii. Rasagiline

ANTIPARKINSON'S AGENTS

OTHER ANTIPARKINSON'S AGENTS	
amantadine ^{AP} bromocriptine carbidopa/levodopa levodopa/carbidopa/entacapone selegiline	AZILECT (rasagiline) carbidopa ELDEPRYL (selegiline) levodopa/carbidopa ODT LODOSYN (carbidopa) PARCOPA (levodopa/carbidopa) PARLODEL (bromocriptine) rasagiline RYTARY (levodopa/carbidopa) SINEMET (levodopa/carbidopa) STALEVO (levodopa/carbidopa/entacapone) ZELAPAR (selegiline)

iii. Quetiapine ER

ANTIPSYCHOTICS, ATYPICAL

SINGLE INGREDIENT	
ABILIFY MAINTENA (aripiprazole)* ^{CL} ABILIFY DISCMELT & ORAL SOLUTION (aripiprazole) aripiprazole tablets clozapine INVEGA SUSTENNA (paliperidone)* ^{CL} INVEGA TRINZA (paliperidone)** ^{CL} LATUDA (lurasidone)*** ^{AP} olanzapine olanzapine ODT quetiapine**** ^{AP} for the 25 mg Tablet Only RISPERDAL CONSTA (risperidone) * ^{CL} risperidone ziprasidone	ABILIFY TABLETS (aripiprazole) ADASUVE (loxapine) aripiprazole discmelt & oral solution ARISTADA (aripiprazole)***** clozapine ODT CLOZARIL (clozapine) FANAPT (iloperidone) FAZACLO (clozapine) GEODON (ziprasidone) GEODON IM (ziprasidone) INVEGA ER (paliperidone) ***** NUPLAZID (pimavanserin) ***** olanzapine IM* paliperidone ER***** quetiapine ER REXULTI (brexipiprazole) RISPERDAL (risperidone) SAPHRIS (asenapine) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) VERSACLOZ (clozapine) VRAYLAR (capripazine) VRAYLAR DOSE PAK (capripazine) ZYPREXA (olanzapine) ZYPREXA IM (olanzapine)* ZYPREXA RELPREVV (olanzapine)

iv. Loprinavir/ritonavir

ANTIRETROVIRALS

COMBINATION PRODUCTS – PROTEASE INHIBITORS	
KALETRA (lopinavir/ritonavir)	lopinavir/ritonavir

v. Oseltamivir

ANTIVIRALS, ORAL		
ANTI-INFLUENZA		
RELENZA (zanamivir) TAMIFLU (oseltamivir)	FLUMADINE (rimantadine) oseltamivir rimantadine	

vi. Metoprolol/HCTZ ER

BETA BLOCKERS^{AP}		
BETA BLOCKER/DIURETIC COMBINATION DRUGS		
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ propranolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol ER/HCTZ ER) LOPRESSOR HCT (metoprolol/HCTZ) metoprolol/HCTZ ^{ER} nadolol/bendroflumethiazide TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)	

vii. Ezetimibe

LIPOTROPICS, OTHER (Non-statins)		
CHOLESTEROL ABSORPTION INHIBITORS		
ZETIA (ezetimibe) ^{AP}	ezetimibe	

Chris Terpening made a motion to approve all New Generic changes as recommended; the motion was seconded by Hazi Nazha. All members were in favor and the motion was approved.

C. New Drug Reviews

i. UTIBRON

COPD AGENTS		
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS^{AP}		
albuterol/ipratropium COMBIVENT RESPIMAT (albuterol/ipratropium) ANORO ELLIPTA (umeclidinium/vilanterol)*	BEVESPI (glycopyrrolate/formoterol) DUONEB (albuterol/ipratropium) STIOLTO RESPIMAT (tiotropium/olodaterol)* UTIBRON (indacaterol/glycopyrrolate)	

Karrie Juengel made a motion to approve the changes to the COPD Agents category as recommended with the addition of Anora Ellipta to Preferred status; the motion was seconded by Hazi Nazha. All members were in favor and the motion was approved.

ii. ILARIS

CYTOKINE & CAM ANTAGONISTS^{CL}

OTHERS	
COSENTYX (secukinumab)*	ACTEMRA subcutaneous (tocilizumab) ILARIS (canakinumab) KINERET (anakinra) ORENCIA subcutaneous (abatacept) OTEZLA (apremilast) STELARA subcutaneous (ustekinumab) TALTZ (ixekizumab) XELJANZ (tofacitinib) XELJANZ XR (tofacitinib)

Chris Terpening made a motion to approve the changes to the Cytokine & CAM Antagonists category as recommended; the motion was seconded by Toni DiChiacchio. All members were in favor and the motion was approved.

iii. VEMLIDY

HEPATITIS B TREATMENTS

BARACLUDE (entecavir) lamivudine HBV TYZEKA (telbivudine)	adefovir entecavir EPIVIR HBV (lamivudine) HEPSERA (adefovir) VEMLIDY (tenofovir alafenamide fumarate)
---	---

Hazi Nazha made a motion to approve the changes to the Hepatitis B Treatments category as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.

iv. RAYALDEE

HYPERPARATHYROID AGENTS^{AP}

doxercalciferol paricalcitol capsule	HECTOROL (doxercalciferol) paricalcitol injection RAYALDEE (calcifediol) SENSIPAR (cinacalcet) ZEMPLAR (paricalcitol)
---	--

Karrie Juengel made a motion to approve the changes to the Hyperparathyroid Agents category as recommended; the motion was seconded by Hazi Nazha. All members were in favor and the motion was approved.

v. ADLYXIN

HYPOGLYCEMICS, GLP-1 AGONISTS

BYDUREON (exenatide) BYETTA (exenatide) VICTOZA (liraglutide)	ADLYXIN (lixisenatide) SYMLIN (pramlintide)* TANZEUM (albiglutide) TRULICITY (dulaglutide)	
---	---	--

Karrie Juengel made a motion to approve the changes to the Hypoglycemics, GLP-1 Agonists category as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.

vi. BASAGLAR, SOLIQUA & XULTOPHY

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

HUMALOG (insulin lispro) HUMALOG MIX VIALS (insulin lispro/lispro protamine) HUMULIN VIALS (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	AFREZZA (insulin) ^{CL} APIDRA (insulin glulisine) ^{AP*} BASAGLAR (insulin glargine) HUMALOG PEN/KWIKPEN (insulin lispro) HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMULIN PENS (insulin) NOVOLIN (insulin) SOLIQUA (insulin glargine/lixisenatide) ^{***} TOUJEO SOLOSTAR (insulin glargine) ^{**} TRESIBA (insulin degludec) ^{**} XULTOPHY (insulin degludec/liraglutide) ^{***}	
---	--	--

Chris Terpening and Karrie Juengel made a motion to approve the changes to the Hypoglycemics, Insulin and Related Agents category as recommended; the motion was seconded by Hazi Nazha and Toni DiChiacchio. All members were in favor and the motion was approved.

vii. TRULANCE

IBS/SBS/SELECTED GI AGENTS

AMITIZA (lubiprostone) ^{CL*} LINZESS (linaclotide) ^{CL*}	alosetron** FULYZAQ (crofelemer)* LOTRONEX (alosetron)** MOVANTIK (naloxegol)* RELISTOR INJECTION (methylnaltrexone)* RELISTOR TABLET (methylnaltrexone)* TRULANCE (plecanatide)* VIBERZI (eluxadoline)**	
---	--	--

Steve Neal made a motion to approve the changes to the IBS/SBS/Selected GI Agents category as recommended; the motion was seconded by Chris Terpening. All members were in favor and the motion was approved.

viii. **EUCRISA**

IMMUNOMODULATORS, ATOPIC DERMATITIS^{AP}		
ELIDEL (pimecrolimus) ^{AP}	PROTOPIC (tacrolimus) tacrolimus ointment EUCRISA (crisaborole)	

Karrie Juengel made a motion to approve the changes to the Immunomodulators, Atopic Dermatitis category as recommended; the motion was seconded by Hazi Nazha. All members were in favor and the motion was approved.

VII. Old Business

There was no old business to be discussed at this time.

VIII. Other Business

MAVYRET

HEPATITIS C TREATMENTS^{CL}		
EPCLUSA (sofosbuvir/velpatasvir)* HARVONI (ledipasvir/sofosbuvir)* MAVYRET (pibrentasvir/glecaprevir)* PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) ribavirin SOVALDI (sofosbuvir)* TECHNIVIE (ombitasvir/paritaprevir/ritonavir)* VIEKIRA PAK (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* VIEKIRA XR (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* ZEPATIER (elbasvir/grazoprevir)*	COPEGUS (ribavirin) DAKLINZA (daclatasvir)* MODERIBA 400 mg, 600 mg MODERIBA DOSE PACK OLYSIO (simeprevir)* REBETOL (ribavirin) RIBASPHERE RIBAPAK (ribavirin) RIBASPHERE 400 mg, 600 mg (ribavirin)	

CHC made a recommendation to make an exception to the 6-month requirement for new drugs. Dr. Biczak presented the clinical benefits of the new drug MAVYRET that just recently came on the market. Chris Terpening made a motion to accept the recommendation of adding MAVYRET as a Preferred agent. Toni DiChiacchio seconded the motion. All were in favor and motion passed as recommended.

IX. Next Meeting – October 25, 2017, 9 AM - 5 PM, Civic Center, 2nd Floor

Dr Henry provided a confirmation of the planned date and Doug Sorvig provided the updated start time for the next meeting.

X. Adjournment

Dr. Henry adjourned the meeting at 4:38pm

DRAFT